🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMarketplace & ListingsTelehealth prescriber directory — anyone have experience?

Telehealth prescriber directory — anyone have experience?

bbq_ray_KC Wed, Feb 18, 2026 at 6:46 PM 13 replies 973 viewsPage 1 of 3
bbq_ray_KC
Member
378
1,678
Jul 2024
Kansas City, KS
Feb 18, 2026 at 6:46 PM#1

Putting this up for argument rather than for agreement. I have read it twice and I am still not certain what it supports.

Denials are usually procedural rather than clinical, and the order that works reflects that. Get the denial reason in writing, because it names the criterion you failed. Then supply the documentation that criterion asks for — usually documented BMI with a comorbidity, or a failed prior therapy. Then appeal, and ask for a peer-to-peer review, because a prescriber talking to a reviewing clinician resolves a large fraction of denials that written appeals do not. Manufacturer copay assistance is separate and applies mainly to commercial insurance, and patient assistance programmes are means-tested rather than a discount.

Where I think it is weakest: the subgroup findings are the part I trust least — with enough subgroups something is always significant, and these were not all pre-registered.

The bit I cannot resolve on my own is what actually works on a prior-authorisation denial, as opposed to the list of things that sound like they should work. Happy to be told the question itself is wrong.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
7 2COA_Karl, MikeFit_NJ, InsuranceTom and 4 others
Reply Quote Save Share Report
NurseKim_ATL
Senior Member
1,678
7,234
Feb 2024
Atlanta, GA
Feb 18, 2026 at 7:06 PM#2
bbq_ray_KC said:
Denials are usually procedural rather than clinical, and the order that works reflects that.
bbq_ray_KC said:
...regarding the discontinuation data for cost and coverage...

I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."

Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.

This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.

6 1raj_cambridge, ingrid_STO, pete_nash and 3 others
Reply Quote Save Share Report
SarahChen_PharmD
VIP Member
4,567
22,341
Dec 2023
San Diego, CA
Feb 18, 2026 at 7:26 PM#3
bbq_ray_KC said:
Denials are usually procedural rather than clinical, and the order that works reflects that.

I read this differently from bbq_ray_KC, on substance rather than tone. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.

5 0paul_denver, TinaHashiRN, robert_kc and 2 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
GenomicsKate
Member
345
1,890
Oct 2024
Cambridge, MA
Feb 18, 2026 at 7:46 PM#4
SarahChen_PharmD said:
The affordability discussion here usually stops at individual tactics.
SarahChen_PharmD said:
...compounded vs brand cost and coverage...

This debate comes up weekly and I think both sides have valid points:

Pro-brand: FDA-approved, manufacturing standards guaranteed, clinical trial data directly applicable

Pro-compounded: 10x cost savings, same active molecule, independent testing available, accessibility

My position: if you can afford brand or have insurance coverage, that's the gold standard. If not, properly tested compounded from a 503B pharmacy is a reasonable alternative. Neither side should shame the other.

4 24Dr.PeteFamMed, claudia_zurich, nancy_portland and 1 other
Reply Quote Save Share Report
anna.melb_AU
Member
678
2,890
Apr 2024
Melbourne, AU
Feb 18, 2026 at 9:31 PM#5
NurseKim_ATL said:
bbq_ray_KC said: ...regarding the discontinuation data for cost and coverage...

Can confirm. Same sequence, different timescale. The detail I would add is minor and it is already implied above.

3 23Dr.LipidDallas, alex_tucson, kevin_tulsa
Reply Quote Save Share Report

Similar Threads

Price comparison: compounded semaglutide — June 202622 replies
Telehealth provider directory — updated quarterly5 replies
Group buy discussion — is it worth organizing?3 replies
Bacteriostatic water sourcing guide — verified suppliers3 replies
Compounded semaglutide price tracker — updated weekly19 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register